19 October 2021 in Endocrine
23 May 2023 in Journal of the Endocrine Society
MBMarilia D’eLboux Guimarães Brescia
Marilia D’eLboux Guimarães Brescia
CJClimério Pereira Nascimento Júnior
Climério Pereira Nascimento Júnior
LNLedo Mazzei Massoni Neto
FMFabio Luiz de Menezes Montenegro
Fabio Luiz de Menezes Montenegro
+5
Backgroud Parathyroid carcinoma (PC) is a rare and challenging disease without clearly understood prognostic factors. Adequate management can improve outcomes. Characteristics of patients treated for PC over time and factors affecting prognosis were analyzed. Methods Retrospective cohort study including surgically treated patients for PC between 2000 and 2021. If malignancy was suspected, free-margin resection was performed. Demographic, clinical, laboratory, surgical, pathological, and follow-up characteristics were assessed. Results Seventeen patients were included. Mean tumor size was 32.5 mm, with 64.7% staged as pT1/pT2. None had lymph node involvement at admission, and two had distant metastases. Parathyroidectomy with ipsilateral thyroidectomy was performed in 82.2%. Mean postoperative Calcium levels were different between patients who developed recurrence versus those who did not (p=0.03). Six patients (40%) had no recurrence during follow-up, two (13.3%) only regional, three (20%) only distant, and four (26.6%) both regional and distant. At 5 and 10 years, 79% and 56% of patients were alive, respectively. Median disease-free survival was 70 months. Neither TNM system nor largest tumor dimension (p=0.29 and p=0.74, respectively) were predictive of death. En bloc resection was not superior to other surgical modality (p=0.97). Time between initial treatment and development of recurrence negatively impacted overall survival rate at 36 months (p=0.01). Conclusion Patients with PC can survive for decades and have indolent disease course. Free margins seem to be the most important factor in initial surgery. Recurrence was common (60%), but those with disease recurrence within 36 months of initial surgery had a lower survival rate.
14 September 2024 in Clinics
Subtotal Parathyroidectomy (S-PTx) and total Parathyroidectomy with immediate Autograft (PTx-AG) are well-established techniques for the treatment of refractory Secondary Hyperparathyroidism (SHPT), with comparable improvements in patients' quality of life and survival. However, the long-term costs after these operations may impact the choice of surgical technique. The objective of the study is to analyze the impact of surgical treatment on medication costs and whether there is any difference between medication use after each procedure, considering impacts on the health system. Prospective and randomized study in patients with severe SHPT undergoing S-PTx and PTx-AG. Analysis of prescribed medication costs in the month before the postoperative period at 1-, 3-, 6-, 12-, and 18 months. Costs were estimated according to government payment system values. The medications of 65 patients after PTx-AG were compared with those of 24 patients after S-PTx. A comparison of the total costs of the period between 38 men and 51 women was also made. There were 89 evaluable cases. Surgery reduced medication costs after 12 months. The median of total drug costs in the analyzed period was R$ 8,375.00 per patient. There was no difference in costs per patient in the S-PTx group compared to the PTx-AG group. The median total costs were R$ 11,063.0 for men and R$ 7,651.0 for women (p = 0.0078). The type of parathyroidectomy did not impact costs after surgery. In the first year after surgery, the use of calcium and calcitriol was more significant than the use of other medications. In the following months, the use of sevelamer is responsible for the highest costs. Men have higher costs in outpatient follow-up after surgery.
4 December 2025 in Revista de Medicina
RBRafaela Mendes Battiferro
Rafaela Mendes Battiferro
Multiple endocrine neoplasia type 1 (MEN1) is a genetic syndrome caused by inactivation of the MEN1 tumor suppressor gene, which confers increased susceptibility to the development of neoplasms, especially endocrine tumors such as parathyroid adenomas.¹ Although it is a rare disease, primary hyperparathyroidism resulting from hyperplasia and/or neoplasia of the parathyroid glands occurs in up to 97% of individuals with the syndrome.² The treatment for hyperparathyroidism is surgical, and the two main techniques currently used are subtotal parathyroidectomy, involving the removal of 3.5 glands, and total parathyroidectomy with autotransplantation, in which all four glands are removed and a graft is prepared in the forearm.³ Although both approaches are employed, the choice of the optimal surgical technique for this condition remains under debate. A single study with a small cohort of 32 participants compared these two procedures and found no significant differences between them.⁴ The choice of surgical technique must consider the risk of recurrent hyperparathyroidism, given the multiglandular nature of the disease, and the risk of complications for example, hypoparathyroidism — defined by inappropriately low PTH levels in the presence of hypocalcemia.⁵ Traditionally, postoperative hypoparathyroidism is considered permanent when it persists for more than six months after surgery.⁶ However, this arbitrary definition is based on patients undergoing thyroidectomy and who do not have MEN1. Patients with MEN1 may have additional factors that delay the recovery of parathyroid function, such as previous malabsorptive surgeries, prolonged hungry bone syndrome, and removal of multiple glands. The latest international hypoparathyroidism guideline, published in 2022, proposed extending this limit to twelve months⁷, recognizing that functional recovery may be slower in specific contexts.
1 June 2025 in VideoEndocrinology™
FVFelipe Augusto Brasileiro Vanderlei
Felipe Augusto Brasileiro Vanderlei
MRMatheus Gerhard Rosenfeld
Matheus Gerhard Rosenfeld
MHMarcus Vinicius Lopes Horiuchi
Marcus Vinicius Lopes Horiuchi
LMLea Maria Zanini Maciel
+1
SAGE-Journals-Accessible-Video-Player 10.1089/ve.2025.0002.M1 sj-vid-1-vde-10.1089_ve.2025.0002
1 January 2026 in Archives of Endocrinology and Metabolism
Objective: This study aims to analyze the clinical characteristics and prognostic factors of patients with parathyroid carcinoma (PC) treated at a tertiary institution. Subjects and methods: This retrospective cohort included 30 patients with PC who were treated between 1970 and 2023 at a single reference center. Clinical, pathological, and survival data were reviewed and prognostic factors were evaluated. Results: Of the 30 cases, 16 (53.3%) were women. Mean age at diagnosis was 45.9 years, median follow-up was 60 months and mean tumor size was 33 mm. Median follow-up was 60 months. Disease recurrence occurred in 16 (53.3%) cases, with disease persistence in three (10.0%). Median disease-free survival was 80 months, with a 57% overall survival rate. Neither gender nor age showed significant impact on survival. Patients with lower-stage tumors (T1 by the AJCC/UICC and T1+T2 by the Shaha classification) had significantly better overall survival (p = 0.004 and p = 0.0018, respectively) and disease-free survival (p = 0.03 and p = 0.04, respectively) than those with more advanced stages (p = 0.03 and p = 0.04, respectively). Additionally, patients who experienced tumor recurrence after 36 months had significantly better survival outcomes than those with earlier recurrences (p = 0.02). Conclusion: Advanced tumor stage (T3 by the Shaha or T2 and above by the AJCC/UICC) is associated with higher mortality in patients with PC. Furthermore, a disease-free interval exceeding 36 months emerged as a relevant factor associated with improved overall survival.